Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

Agile Therapeutics logo

About Agile Therapeutics Stock (NASDAQ:AGRX)

Advanced Chart

Key Stats

Today's Range
$1.51
$1.52
50-Day Range
$1.43
$1.51
52-Week Range
$0.20
$2.63
Volume
120,938 shs
Average Volume
352,864 shs
Market Capitalization
$10.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AGRX Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

AGRX Stock Analysis - Frequently Asked Questions

Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analyst estimates of $1.49 million.
Read the conference call transcript
.

Agile Therapeutics shares reverse split on Wednesday, April 27th 2022.The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/02/2021
Today
8/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGRX
CIK
1261249
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.47 million
Net Margins
-36.24%
Pretax Margin
-36.24%
Return on Equity
N/A
Return on Assets
-147.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.56
Quick Ratio
0.38

Sales & Book Value

Annual Sales
$19.98 million
Price / Sales
0.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.51) per share
Price / Book
-0.27

Miscellaneous

Outstanding Shares
6,856,000
Free Float
6,822,000
Market Cap
$10.35 million
Optionable
Not Optionable
Beta
1.58

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AGRX) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners